BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...or visual content" frameborder="0" scrolling="no" style="width:100%;height:900px;"> Selina Koch AstraZeneca plc Arcus Biosciences Bristol-Myers Squibb Co. I-Mab Biopharma Akeso Biopharma Surface Oncology Inc. Novartis AG Corvus Pharmaceuticals Inc. Tracon...
BioCentury | Jun 7, 2019
Emerging Company Profile

insitro: machine learning with designated data

...Ventures, which invested in insitro's series A. He was SVP and CBO of cancer company Corvus Pharmaceuticals Inc....
...Inc, San Francisco, Calif. BenevolentAI, London, U.K. Calico Life Sciences LLC, South San Francisco, Calif. Corvus Pharmaceuticals Inc....
BioCentury | Jan 30, 2019
Company News

Management tracks: Corvus, Maverick

...Precision oncology company Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) hired Mehrdad Mobasher as VP and CMO. He was a group...
...previously, he was Group CFO of Xtera Ltd. Pankhania succeeds Richard Vellacott as CFO. Elizabeth S. Eaton Corvus Pharmaceuticals Inc. GigaGen...
BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

...and company press releases Company Product Target Study characteristics Partial response Stable disease Checkpoint inhibitors Corvus Pharmaceuticals Inc....
...PD-1 or PD-L1 inhibitors. The majority of the agents target new checkpoint proteins. Among them, Corvus Pharmaceuticals Inc.’s...
...NASDAQ:ADRO), Berkeley, Calif. Aleta Biotherapeutics Inc., Natick, Mass. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Corvus Pharmaceuticals Inc....
BioCentury | Sep 5, 2018
Company News

Management tracks: Agios, Radius

...Business Development and Strategy Alicia Levey to CBO. Laport was VP of clinical development at Corvus Pharmaceuticals Inc....
BioCentury | May 15, 2018
Distillery Therapeutics

Cancer

...for non-small cell lung cancer (NSCLC) and Phase I testing for solid tumors. Vernalis plc, Corvus Pharmaceuticals Inc....
BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

...A2A receptor inhibitors for cancer. The first signs of efficacy in the clinic came from Corvus Pharmaceuticals Inc.’s...
...Corp. (Tokyo:4565) / AstraZeneca plc (LSE:AZN; NYSE:AZN) AZD4635 Ph I/II NSCLC Vernalis plc (LSE:VER) / Corvus Pharmaceuticals Inc....
...Research, Philadelphia, Pa. Arcus Biosciences Inc. (NYSE:RCUS), Hayward, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Corvus Pharmaceuticals Inc....
BioCentury | Mar 16, 2018
Financial News

Corvus prices $69M follow-on

...Cancer company Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) raised $69 million through the sale of 8.1 million shares at $8.50...
...the sale of a 1.1 million share overallotment on March 12. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), Burlingame, Calif. Shannon Lehnbeuter Corvus Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...sclerosis Submit NDA YE17 Coherus BioSciences Inc. (NASDAQ:CHRS) Biosimilar pegfilgrastim (CHS-1701) Neutropenia Resubmit BLA 4Q17 Corvus Pharmaceuticals Inc....
...A receptor delta (GABRD) receptor agonist. Chin is also anticipating additional Phase I data from Corvus Pharmaceuticals Inc....
...Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Centers for Medicare & Medicaid Services, Baltimore, Md. Corvus Pharmaceuticals Inc....
BioCentury | May 26, 2017
Company News

Corvus and Genentech expand 2015 deal, add second combo trial

...receptor (ADORA2A) antagonist , from Vernalis plc (LSE:VER). Tecentriq is a humanized mAb against PD-L1. Corvus Pharmaceuticals Inc....
...Calif. Genentech Inc. , South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer Alex Himes CPI-444 Tecentriq Corvus Pharmaceuticals Inc. Genentech...
Items per page:
1 - 10 of 29
BioCentury | Jan 16, 2021
Product Development

Arcus’ CD73 inhibitor challenges AZ’s oleclumab, at least six others follow in oncology: Data Byte

...or visual content" frameborder="0" scrolling="no" style="width:100%;height:900px;"> Selina Koch AstraZeneca plc Arcus Biosciences Bristol-Myers Squibb Co. I-Mab Biopharma Akeso Biopharma Surface Oncology Inc. Novartis AG Corvus Pharmaceuticals Inc. Tracon...
BioCentury | Jun 7, 2019
Emerging Company Profile

insitro: machine learning with designated data

...Ventures, which invested in insitro's series A. He was SVP and CBO of cancer company Corvus Pharmaceuticals Inc....
...Inc, San Francisco, Calif. BenevolentAI, London, U.K. Calico Life Sciences LLC, South San Francisco, Calif. Corvus Pharmaceuticals Inc....
BioCentury | Jan 30, 2019
Company News

Management tracks: Corvus, Maverick

...Precision oncology company Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) hired Mehrdad Mobasher as VP and CMO. He was a group...
...previously, he was Group CFO of Xtera Ltd. Pankhania succeeds Richard Vellacott as CFO. Elizabeth S. Eaton Corvus Pharmaceuticals Inc. GigaGen...
BioCentury | Nov 17, 2018
Product Development

Betting Combos on Biomarkers

...and company press releases Company Product Target Study characteristics Partial response Stable disease Checkpoint inhibitors Corvus Pharmaceuticals Inc....
...PD-1 or PD-L1 inhibitors. The majority of the agents target new checkpoint proteins. Among them, Corvus Pharmaceuticals Inc.’s...
...NASDAQ:ADRO), Berkeley, Calif. Aleta Biotherapeutics Inc., Natick, Mass. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Corvus Pharmaceuticals Inc....
BioCentury | Sep 5, 2018
Company News

Management tracks: Agios, Radius

...Business Development and Strategy Alicia Levey to CBO. Laport was VP of clinical development at Corvus Pharmaceuticals Inc....
BioCentury | May 15, 2018
Distillery Therapeutics

Cancer

...for non-small cell lung cancer (NSCLC) and Phase I testing for solid tumors. Vernalis plc, Corvus Pharmaceuticals Inc....
BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

...A2A receptor inhibitors for cancer. The first signs of efficacy in the clinic came from Corvus Pharmaceuticals Inc.’s...
...Corp. (Tokyo:4565) / AstraZeneca plc (LSE:AZN; NYSE:AZN) AZD4635 Ph I/II NSCLC Vernalis plc (LSE:VER) / Corvus Pharmaceuticals Inc....
...Research, Philadelphia, Pa. Arcus Biosciences Inc. (NYSE:RCUS), Hayward, Calif. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Corvus Pharmaceuticals Inc....
BioCentury | Mar 16, 2018
Financial News

Corvus prices $69M follow-on

...Cancer company Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) raised $69 million through the sale of 8.1 million shares at $8.50...
...the sale of a 1.1 million share overallotment on March 12. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS), Burlingame, Calif. Shannon Lehnbeuter Corvus Pharmaceuticals Inc....
BioCentury | Oct 6, 2017
Finance

Coasting on catalysts

...sclerosis Submit NDA YE17 Coherus BioSciences Inc. (NASDAQ:CHRS) Biosimilar pegfilgrastim (CHS-1701) Neutropenia Resubmit BLA 4Q17 Corvus Pharmaceuticals Inc....
...A receptor delta (GABRD) receptor agonist. Chin is also anticipating additional Phase I data from Corvus Pharmaceuticals Inc....
...Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Centers for Medicare & Medicaid Services, Baltimore, Md. Corvus Pharmaceuticals Inc....
BioCentury | May 26, 2017
Company News

Corvus and Genentech expand 2015 deal, add second combo trial

...receptor (ADORA2A) antagonist , from Vernalis plc (LSE:VER). Tecentriq is a humanized mAb against PD-L1. Corvus Pharmaceuticals Inc....
...Calif. Genentech Inc. , South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Cancer Alex Himes CPI-444 Tecentriq Corvus Pharmaceuticals Inc. Genentech...
Items per page:
1 - 10 of 29